Christina Sina
Co-Project Leader


Christina Sina joined the Wyss Zurich CeNeReg team in January 2016 and became Co-Project Leader in January 2018. She is responsible for coordinating study drug production, logistics, and supply. In addition, she is the scientific coordinator of Martin Schwab and supports the translation of his basic Nogo-A research into clinical application of the anti-Nogo-A antibody therapy. Christina holds a PhD in Immunology from the University of Zurich and worked in a PR agency for life science and health care communication.

Tel: +41 44 635 32 62

Eduardo Vianna
Co-Project Leader


Eduardo Vianna joined the Wyss Zurich CeNeReg team in January 2018 as Co-Project Leader. He is the CEO of the biotech startup company NovaGo Therapeutics AG and leads all clinical and business development activities related to the Nogo-A therapy. He holds a PhD in Neuroscience as well as an MBA and has more than 15 years of experience in neuroscience research and development. Prior to his current assignments, Eduardo Vianna worked for both Merck Serono and Roche, serving in global roles of increasing responsibility within medical affairs, clinical development, and portfolio management.

Michael Maurer
Senior Scientist


Michael Maurer is part of the Wyss Zurich CeNeReg team since January 2016. Originally coming from the pharmaceutical industry and being educated as chemical laboratory technician, he later received his M.Sc. in Biotechnology from ETH Zurich and his Ph.D. in Immunology from the University of Zurich. As Senior Scientist in the Schwab laboratory, his research focuses on Nogo-A antigens and anti-Nogo-A antibodies. Within the Wyss Zurich CeNeReg project, he serves as consultant for all antibody-related tasks and questions.

Tel: +41 44 635 32 13